Correlation Between Programmed Cell Death Ligand1 (PD-L1) Expression and Clinical Parameters in Colorectal Carcinoma

Abstract

Abstract
 
 
 Objectives: Programmed Cell Death Ligand1 (PD-L1) tissue expression in CRC (colorectal cancer) displays conflicting results among various studies. We aimed to identify the rate of PD-L1 positivity in colorectal carcinoma, and it's immune infiltrating cells, their relationship with clinicopathologic parameters of patients, and to correlate the results with other studies.
 
 Methods: PD-L1 antibody retrospectively analyzed immunohistochemically in tissue microarray blocks of 99 specimens with colonic and rectal carcinomas operated between January 2015 to December 2017. A comparison performed between PD-L1 expression in tumor cells (TCs) as well as tumor-infiltrating immune cells (TIICs) for age, sex, histological differentiation, the primary tumor location, number of involved lymph nodes, angiolymphatic invasion, and TNM stage.
 
 Results: Of the 99 patients, the median age was 54.5 (range: 18 to 83) years. Fourteen samples were PD-L1 positive in TCs, increased to 32% in TIICs. A significant expression of PD-L1in TCs was correlated with medullary histology (p= 0.03), number of the involved lymph nodes (p= 0.02), distant metastasis (p= 0.001), and TNM stage (p= 0.0001). The PD-L1 status in TIICs was again connected with adverse clinical and pathological parameters.
 
 Conclusions: The expression of PD-L1 in TCs and TIICs is associated significantly with advanced cancer or lymphatic invasion in patients who underwent surgery after a diagnosis of CRC. The research designates the significance of estimation of TCs and TIICs in correlation to clinicopathologic characteristics of patients a finding that could produce a piece of evidence for precise electing immunotherapy.
 
 
 
 Keywords: Programmed cell death ligand1, colorectal carcinoma, Tissue microarray study, Immunohistochemistry.
 
 

Immunohistochemical Expression of Programmed Death Ligand- 1 (PD-L1) in Colorectal Carcinoma; A Cross-sectional Study

“…In diverse studies, the IHC expression of PD-L1 on tumor cells ranges from 4.4% to 88.8%. The present study is consistent with studies by Zhu H et al and Aziz ZW et al ( 16 , 17 , 18 , 19 ). These variations could be ascribed to scoring system differences, intratumoral staining heterogeneity due to tissue microarrays versus whole slides, positive cut-offs used, and other factors.…”